Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

A framework for variation discovery and genotyping using next-generation DNA sequencing data

DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,216 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2× · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095192 · Cited by 1,874 · see citing works

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · see citing works

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509 · see citing works

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191 · see citing works

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Beltra, J., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,091 · see citing works

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Patnaik, A., Kang, S. P., Rasco, D. W., Papadopoulos, K. P., Elassaiss‐Schaap, J., Beeram, M., Drengler, R. L., Chen, C., Smith, L. S., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 803 · see citing works

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

O’Reilly, E. M., Oh, D.-Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S.-C., Vlahovic, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1588 · Cited by 767 · see citing works

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 738 · see citing works

Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells

Haniffa, M. A., Shin, A., Bigley, V., McGovern, N. N., Teo, P., See, P., Wasan, P. S., Wang, X.-N., Malinarich, F., Malleret, B., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.012 · Cited by 726 · see citing works

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526 · see citing works

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · see citing works

Four functionally distinct populations of human effector-memory CD8+ T lymphocytes

Romero, P., Zippelius, A., Kurth, I., Pittet, M. J., Touvrey, C., Iancu, E. M., Corthesy, P., Devevre, E., Speiser, D. E., & Rufer, N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4112 · Cited by 405 · see citing works

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382 · see citing works

Regulation of the Germinal Center Response

Stebegg, M., Kumar, S. D., Silva-Cayetano, A., Fonseca, V. R., Linterman, M. A., & Graca, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02469 · Cited by 349 · see citing works

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307 · see citing works

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2839 · Cited by 295 · see citing works

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer

Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · see citing works

An interactive reference framework for modeling a dynamic immune system

Spitzer, M. H., Gherardini, P. F., Fragiadakis, G. K., Bhattacharya, N., Yuan, R. T., Hotson, A. N., Finck, R., Carmi, Y., Zunder, E. R., Fantl, W. J., et al. (2015) · Science · doi:10.1126/science.1259425 · Cited by 239 · see citing works

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 235 · see citing works

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma

Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 201 · see citing works

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

Cohn, L. B., Chatterjee, B., Esselborn, F., Smed‐Sörensen, A., Nakamura, N., Chalouni, C. M., Lee, B.-C., Vandlen, R. A., Keler, T., Lauer, P., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121251 · Cited by 200 · see citing works

Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1047 · Cited by 199 · see citing works

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

Tokito, T., Azuma, K., Kawahara, A., Ishii, H., Yamada, K., Matsuo, N., Kinoshita, T., Mizukami, N., Ono, H., Kage, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.020 · Cited by 187 · see citing works

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials

Upadhaya, S., Neftelino, S. T., Hodge, J. P., Oliva, C., Campbell, J. R., & Yu, J. X. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00204-y · Cited by 183 · see citing works

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

van Hooren, L., Vaccaro, A., Ramachandran, M., Vazaios, K., Libard, S., van de Walle, T., Georganaki, M., Huang, H., Pietilä, I., Lau, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24347-7 · Cited by 164 · see citing works

Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Wainberg, Z. A., Höchster, H. S., Kim, E. J.-H., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A. R., Jain, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0099 · Cited by 158 · see citing works

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

Hartmann, F. J., Babdor, J., Gherardini, P. F., Amir, E.-A. D., Jones, K., Sahaf, B., Marquez, D. M., Krutzik, P., O’Donnell, E., Sigal, N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.049 · Cited by 124 · see citing works

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Tempero, M. A., Oh, D., Tabernero, J. M., Reni, M., Cutsem, E. V., Hendifar, A. E., Waldschmidt, D., Starling, N., Bachet, J., Chang, H. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.070 · Cited by 120 · see citing works

Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance

Ding, C., Ma, Y., Chen, X., Liu, M., Cai, Y., Hu, X., Xiang, D., Nath, S. K., Zhang, H., Ye, H., et al. (2013) · Nature Communications · doi:10.1038/ncomms3813 · Cited by 78 · see citing works

Achieving high-sensitivity for clinical applications using augmented exome sequencing

Patwardhan, A. J., Harris, J., Leng, N., Bartha, G. T., Church, D. M., Luo, S. J., Haudenschild, C. D., Pratt, M., Zook, J. M., Salit, M., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0197-4 · Cited by 57 · see citing works

APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

Filbert, E. L., Björck, P., Srivastava, M. K., Bahjat, F. R., & Yang, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02814-2 · Cited by 37 · see citing works

Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming

Diamond, M. S., Lin, J., & Vonderheide, R. H. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0785 · Cited by 30 · see citing works

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

Yang, Z., Deng, Y., Cheng, J., Wei, S., Luo, H., & Liu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695006 · Cited by 20 · see citing works

Comprehensive Immune Monitoring of Clinical Trials to Advance Human ImmunotherapyPreprint

Hartmann, F. J., Babdor, J., Gherardini, P. F., Amir, E.-A. D., Jones, K. B., Sahaf, B., Marquez, D. M., Krutzik, P. O., O'Donnell, E. A., Sigal, N., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/489765 · Cited by 14 · see citing works

Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.

Lyman, J. P., Doucette, A. G., Zheng-Lin, B., Cabanski, C. R., Maloy, M., Bayless, N. L., Xu, J., Smith, W., Karakunnel, J. J., Fairchild, J. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.528 · Cited by 5 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Therapeutic developments in pancreatic cancer

Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 427 · see citing works

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 355 · see citing works

Therapeutic targeting of tumour myeloid cells

Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305 · see citing works

Current and future immunotherapeutic approaches in pancreatic cancer treatment

Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 247 · see citing works

Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer

Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 213 · see citing works

Barriers and opportunities in pancreatic cancer immunotherapy

Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 167 · see citing works

Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer

Bianchi, A., Silva, I. D. C., Deshpande, N., Singh, S. P., Mehra, S., Garrido, V. T., Guo, X., Nivelo, L. A., Kolonias, D. S., Saigh, S. J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1046 · Cited by 138 · see citing works

Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas

Kinker, G. S., Vitiello, G. A. F., Diniz, A. B., Cabral-Piccin, M. P., Pereira, P. H. B., Carvalho, M. L. R., Ferreira, W. A. S., Chaves, A. S., Rondinelli, A. J., Gusmão, A. F., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328697 · Cited by 130 · see citing works

The Role of Immunotherapy in Pancreatic Cancer

Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 100 · see citing works

Consensus, debate, and prospective on pancreatic cancer treatments

Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 99 · see citing works

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

Croft, M., Salek‐Ardakani, S., & Ware, C. F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01053-9 · Cited by 98 · see citing works

Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer

Dyikanov, D., Zaitsev, A., Васильева, Т. В., Wang, I., Sokolov, A. A., Bolshakov, E. S., Frank, A., Turova, P., Golubeva, O., Gantseva, A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.008 · Cited by 91 · see citing works

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma

Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 88 · see citing works

Leveraging big data of immune checkpoint blockade response identifies novel potential targets

Barèche, Y., Kelly, D., Aghababazadeh, F. A., Nakano, M., Esfahani, P. N., Tkachuk, D., Mohammad, H., Samstein, R. M., Lee, C., Morris, L. G. T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.084 · Cited by 82 · see citing works

Digestive cancers: mechanisms, therapeutics and management

Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 85 · see citing works

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80 · see citing works

A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance

Zhou, J., Lyu, N., Wang, Q., Yang, M. J., Kimchi, E. T., Cheng, K., Joshi, T., Tukuli, A. R., Staveley-O’Carroll, K. F., & Li, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216457 · Cited by 71 · see citing works

Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept

Luo, W., Wen, T., & Qu, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02935-3 · Cited by 69 · see citing works

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer

Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9366 · Cited by 72 · see citing works

Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer

Shakiba, M., & Tuveson, D. A. (2025) · Nature Immunology · doi:10.1038/s41590-025-02134-6 · Cited by 75 · see citing works

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Zhou, Z., der Jeught, K. V., Li, Y., Sharma, S., Yu, T., Moulana, I., Liu, S., Wan, J., Territo, P. R., Opyrchal, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300548 · Cited by 65 · see citing works

Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 66 · see citing works

Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer

Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 68 · see citing works

Improving outcomes of patients with pancreatic cancer

Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 66 · see citing works

The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities

Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 69 · see citing works

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Laethem, J. V., Borbath, I., Prenen, H., Geboes, K., Lambert, A., Mitry, E., Cassier, P. A., Blanc, J., Pilla, L., Feliú, J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00263-8 · Cited by 65 · see citing works

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms

Sivakumar, S., Jainarayanan, A., Arbe-Barnes, E. H., Sharma, P. K., Leathlobhair, M. N., Amin, S., Reiss, D. J., Heij, L. R., Hegde, S., Magen, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55424-2 · Cited by 67 · see citing works

Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment

Sun, C., Yin, M., Cheng, Y., Kuang, Z., Liu, X., Wang, G., Wang, X., Yuan, K., Min, W., Dong, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01801 · Cited by 59 · see citing works

Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients

Gyawali, B., & Booth, C. M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00516-8 · Cited by 58 · see citing works

T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Orlen, M., Vostrejs, W. P., Sor, R., McDevitt, J. C., Kemp, S. B., Kim, I., Kramer, A. B., Shifrin, N. T., Markosyan, N., Clendenin, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1475 · Cited by 58 · see citing works

Harnessing the potential of CD40 agonism in cancer therapy

Zhou, Y., Richmond, A. J., & Yan, C. W. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.002 · Cited by 55 · see citing works

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Wattenberg, M. M., Coho, H., Herrera, V. M., Graham, K. L., Stone, M. L., Xue, Y., Chang, R. B., Cassella, C. R., Liu, M., Choi-Bose, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adj5097 · Cited by 52 · see citing works

Nanomedicines for Overcoming Cancer Drug Resistance

Hu, T., Gong, H., Xu, J., Huang, Y., Wu, F., & He, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081606 · Cited by 55 · see citing works

Clinical immunotherapy in pancreatic cancer

Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54 · see citing works

Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy

Gong, L., Luo, J., Yang, E., Ru, B., Qi, Z., Yang, Y., Rani, A., Purohit, A., Zhang, Y., Guan, G., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.004 · Cited by 55 · see citing works

Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers

Chiaravalli, M., Spring, A., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2022) · Cells · doi:10.3390/cells11193033 · Cited by 50 · see citing works

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer

Klein, L., Tu, M., Krebs, N., Urbach, L., Grimm, D. T., Latif, M. U., Penz, F., Blandau, A., Wu, X., Samuel, R. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55330-7 · Cited by 46 · see citing works

Targeting neutrophils for cancer therapy

Kwak, J., & Houghton, A. M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01210-8 · Cited by 51 · see citing works

Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer

Sanctis, F. D., Dusi, S., Caligola, S., Anselmi, C., Petrova, V., Rossi, B., Angelini, G., Erdeljan, M., Wöll, S., Schlitter, A. M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.04.021 · Cited by 44 · see citing works

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Zheng, R., Liu, X., Zhang, Y., Liu, Y., Wang, Y.-P., Guo, S., Jin, X., Zhang, J., Guan, Y., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383978 · Cited by 43 · see citing works

Facts and Hopes of CD40 Agonists in Cancer Immunotherapy

McVey, J. C., & Beatty, G. L. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1660 · Cited by 44 · see citing works

Dendritic cell subsets and implications for cancer immunotherapy

Chen, M. Y., Zhang, F., Goedegebuure, S. P., & Gillanders, W. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393451 · Cited by 41 · see citing works

Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future

Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 53 · see citing works

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Sha, H., Tong, F., Ni, J., Sun, Y., Zhu, Y., Qi, L., Li, X., Li, W., Yang, Y., Gu, Q., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01857-6 · Cited by 39 · see citing works

Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma

Kim, I., Diamond, M. S., Yuan, S., Kemp, S. B., Kahn, B., Li, Q., Lin, J. H., Li, J., Norgard, R. J., Thomas, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46048-7 · Cited by 38 · see citing works

Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma

Mou, W., Deng, Z., Zhu, L., Jiang, A., Lin, A., Xu, L., Deng, G., Huang, H., Guo, Z., Zhu, B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1727 · Cited by 36 · see citing works

Reshaping the immune microenvironment and reversing immunosenescence by natural products: Prospects for immunotherapy in gastric cancer

Cao, Z., Wang, Z., Li, Y., Li, T. X., Tao, X., & Niu, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.002 · Cited by 35 · see citing works

The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer

Stouten, I., van Montfoort, N., & Hawinkels, L. J. A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108707 · Cited by 34 · see citing works

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Lynce, F. C., Mainor, C. B., Donahue, R. N., Geng, X., Jones, G., Schlam, I. M., Wang, H., Toney, N. J., Jochéms, C., Schlom, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46961-x · Cited by 34 · see citing works

The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer

Larson, A. C., Doty, K. R., & Solheim, J. C. (2024) · Cancer Medicine · doi:10.1002/cam4.7287 · Cited by 33 · see citing works

Tumor necrosis factor superfamily signaling: life and death in cancer

Ababneh, O. E., Nishizaki, D., Kato, S., & Kurzrock, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10206-6 · Cited by 36 · see citing works

Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 32 · see citing works

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

Fu, Q., Chen, Y., Huang, D., Guo, C., Zhang, X., Xiao, W., Xue, X., Zhang, Q., Li, X., Gao, S., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13383-w · Cited by 35 · see citing works

Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial

Cheng, K., Li, X., Lv, W., Zhao, G., Zhou, R., Chen, C., Yang, H., Li, R., Li, Z., Chen, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02031-8 · Cited by 33 · see citing works

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

Zhai, Y., Li, G., Pan, C., Yu, M., Hu, H., Wang, D., Shi, Z., Jiang, T., & Zhang, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217541 · Cited by 33 · see citing works

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Balsano, R., Zanuso, V., Pirozzi, A., Rimassa, L., & Bozzarelli, S. (2023) · Current Oncology · doi:10.3390/curroncol30040293 · Cited by 33 · see citing works

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Hassan, S., Awasthi, N., Ponna, S., & von Holzen, U. W. (2023) · Biomedicines · doi:10.3390/biomedicines11072000 · Cited by 31 · see citing works

Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma

Joseph, A. M., Aiyan, A. A., al-Ramadi, B. K., Singh, S. K., & Kishore, U. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323198 · Cited by 32 · see citing works

Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems

Lencioni, G., Gregori, A., Toledo, B., Rebelo, R., Immordino, B., Amrutkar, M., Xavier, C. P. R., Kocijancic, A., Pandey, D. P., Perán, M., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.002 · Cited by 31 · see citing works

Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer

Hogg, G. D., Weinstein, A. G., Kingston, N. L., Liu, X., Dres, O. M., Kang, L., Lander, V. E., Kao, Y., Ahmad, F. F., Knolhoff, B. L., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp3978 · Cited by 31 · see citing works

Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy

Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaı̈b, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 31 · see citing works

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

Graziano, V., Dannhorn, A., Hulme, H., Williamson, K., Buckley, H., Karim, S. A., Wilson, M., Lee, S. Y., Kaistha, B. P., Islam, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006457 · Cited by 29 · see citing works

Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer

Blise, K. E., Sivagnanam, S., Betts, C. B., Betre, K., Kirchberger, N. C., Tate, B. J., Furth, E. E., Costa, A. D., Nowak, J. A., Wolpin, B. M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0873 · Cited by 30 · see citing works

Immune vulnerabilities of mutant KRAS in pancreatic cancer

Cheng, N. C., & Vonderheide, R. H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.004 · Cited by 30 · see citing works

Next-generation CD40 agonists for cancer immunotherapy

Andersson, H., Nyesiga, B., Hermodsson, T., Smith, K. E., Hägerbrand, K., Lindstedt, M., & Ellmark, P. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357714 · Cited by 30 · see citing works

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 30 · see citing works

A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies

Jian, C.-Z., Li, L., Hsu, C., Chen, Y.-H., Hsu, C., Tan, C., & Ou, D. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103893 · Cited by 28 · see citing works

CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges

Abken, H. (2025) · Nature reviews: Gastroenterology & hepatology · doi:10.1038/s41575-025-01062-y · Cited by 27 · see citing works

Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape

Wang, Z., Zhong, H., Liang, X.-H., & Ni, S.-L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024921 · Cited by 32 · see citing works

The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives

Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 29 · see citing works

Precision treatment of pancreatic ductal adenocarcinoma

Wei, H., & Ren, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216636 · Cited by 25 · see citing works

Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?

Yoon, A. R., Hong, J., Jung, B., Ahn, H. M., Zhang, S., & Yun, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216456 · Cited by 25 · see citing works

Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges

Lim, S. H., Beers, S. A., Al‐Shamkhani, A., & Cragg, M. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1014 · Cited by 24 · see citing works

Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies

Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 26 · see citing works

Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy

Fanijavadi, S., Thomassen, M., & Jensen, L. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020515 · Cited by 24 · see citing works

Bioengineering Approaches for the Pancreatic Tumor Organoids Research and Application

Song, T., Kong, B., Liu, R., Luo, Y., Wang, Y., & Zhao, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300984 · Cited by 24 · see citing works

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Callahan, M. K., Amin, A., Kaye, F. J., Morse, M. A., Taylor, M. H., Peltola, K. J., Sharma, P., O'Reilly, E. M., Meadows-Shropshire, S., O’Brien, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007883 · Cited by 23 · see citing works

Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds

Minaei, E., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.023 · Cited by 24 · see citing works

Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment

Vitorakis, N., Gargalionis, A. N., Papavassiliou, K. A., Adamopoulos, C., & Papavassiliou, A. G. (2024) · Cancers · doi:10.3390/cancers16162876 · Cited by 22 · see citing works

NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway

Chen, E., Wang, Q., Wang, L., Huang, Z., Yang, D., Zhao, C., Chen, W., Zhang, S., Xiong, S., He, Y., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70045 · Cited by 22 · see citing works

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results

Chick, R. C., Gunderson, A. J., Rahman, S., & Cloyd, J. M. (2023) · Cancers · doi:10.3390/cancers15153967 · Cited by 22 · see citing works

A Photoactivatable Self-Assembled Nanoagonist for Synergistic Therapy against Pancreatic Ductal Adenocarcinoma

Xu, X., Li, T., Yang, T., Liu, F., Guo, Z., Wu, H. Y., Tang, Y., & Chen, H. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02959 · Cited by 22 · see citing works

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

Dong, H., Zhang, Z., Ni, M., Xu, X., Luo, Y., Wang, Y., Zhang, H., & Chen, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01246-9 · Cited by 23 · see citing works

Novel Therapies for Pancreatic Cancer

Chung, V., Mizrahi, J. D., & Pant, S. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00279 · Cited by 20 · see citing works

Polyphenol-based pH-responsive nanoparticles enhance chemo-immunotherapy in pancreatic cancer

Li, J., Dai, Y., Wang, T., Zhang, X., Du, P., Dong, Y., & Jiao, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.021 · Cited by 20 · see citing works

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

Kocher, F., Puccini, A., Untergasser, G., Martowicz, A., Zimmer, K., Pircher, A., Baca, Y., Xiu, J., Haybaeck, J., Tymoszuk, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0275 · Cited by 20 · see citing works

Advancements in Systemic Therapy for Pancreatic Cancer

Brown, T. J., Reiss, K. A., & O’Hara, M. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397082 · Cited by 20 · see citing works

Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment

Finan, J. M., Guo, Y., Goodyear, S. M., & Brody, J. R. (2024) · JCO oncology advances. · doi:10.1200/oa-24-00050 · Cited by 20 · see citing works

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook

Tran, L. C., Özdemir, B. C., & Berger, M. D. (2023) · Pharmaceuticals · doi:10.3390/ph16101411 · Cited by 18 · see citing works

Advances in immunotherapy and targeted therapy for pancreatic cancer

Zhou, X., Wang, X., Yang, S., & Huang, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000074 · Cited by 19 · see citing works

Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies

du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 20 · see citing works

Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy

Xue, C., Zhao, S., Zhou, Y., Chen, Z., Liu, J., Deng, S., Zeng, L., Zhao, H., Xu, Z., Li, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.015 · Cited by 18 · see citing works

Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy

Montagne, J. M., Jaffee, E. M., & Fertig, E. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200660 · Cited by 18 · see citing works

“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”

Kronig, M.-N., Wehrli, M., Salas‐Benito, D., & Maus, M. V. (2023) · Immunological Reviews · doi:10.1111/imr.13273 · Cited by 18 · see citing works

The Crosstalk with CXCL10‐Rich Tumor‐Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape

Yin, H., Chen, Q., Gao, S., Shoucair, S., Xie, Y., Habib, J. R., He, T., Gan, W., Wang, J., Zhang, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202417724 · Cited by 18 · see citing works

Pancreatic cancer is feeling the heat

Maru, S. Y., & Jaffee, E. M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010124 · Cited by 18 · see citing works

Stimuli-responsive heparin-drug conjugates co-assembled into stable nanomedicines for cancer therapy

Fang, Z., Lin, L., Li, Z., Gu, L., Pan, D., Li, Y., Chen, J., Ding, H., Tian, X., Gong, Q., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.016 · Cited by 18 · see citing works

Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists

Fromm, G. J., de Silva, S., & Schreiber, T. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1236332 · Cited by 17 · see citing works

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review

Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 18 · see citing works

343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer

Maurer, D. M., Yu, J. X., Skłodowski, K., Tognetti, M., Reiter, L., Bruderer, R., Vowinckel, J., Pfeiffer, S. M., O’Hara, M. H., O'Reilly, E. M., et al. (2021) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2021-sitc2021.343 · Cited by 1 · see citing works

Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.

Padrón, L., Maurer, D. M., O’Hara, M. H., O'Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G. A., Rahma, O. E., Lyman, J. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4010

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?

Melief, C. J. M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100788 · Cited by 2 · see citing works

Distinct Treatment-Related Immunologic Biomarkers Are Identified in PDAC

(2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2022-110

Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma

Yang, S., Kuo, S., Lee, J., Chen, B., Shan, Y., Tien, Y., Chiu, S.-C., Cheng, A., & Yeh, K. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03821-3 · Cited by 5 · see citing works